Skip to content

Brief report: Ketamine-assisted "bridge therapy" for opioid tapering in complex cases.

Mariana C De Oliveira, Cláudia C De Araujo Palmeira, André B Negrão, Ziyad A Hadi, Julia R Arana, Rita De Cássia Ferreira Duarte, Joice L P Da Silva, Gustavo K Matsui, João F D Rapozero, Douglas H Crispim, André Malbergier, João M Castaldelli-Maia

The American journal on addictions January 28, 2026 DOI: 10.1111/ajad.70131 via PubMed

Summary

AI-generated from the abstract

A 25-year-old woman with opioid use disorder, chronic pain, and major depressive disorder received eight weekly intravenous ketamine infusions (0.5 mg/kg) alongside a gradual reduction of her methadone dose. After the protocol, her methadone dosage was cut by 50%, and she experienced better control of pain and cravings, fewer withdrawal symptoms, and increased participation in psychotherapy. The report suggests that ketamine-assisted bridge therapy may help support opioid tapering in patients with multiple co-occurring conditions.

Study at a glance

Characteristics Case study Case report Peer reviewed
Sample size 1
Population 25-year-old woman with opioid use disorder, chronic pain, and major depressive disorder
Intervention Intravenous ketamine infusions
Dose 0.5 mg/kg weekly
Duration 8-week protocol
Citations 1
Key finding Ketamine-assisted bridge therapy enabled a 50% reduction in methadone dosage with improvements in pain, cravings, withdrawal symptoms, and psychotherapy engagement.

Abstract

Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25-year-old woman with OUD, chronic pain, and major depressive disorder underwent an 8-week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Methadone dosage was reduced by 50%, with improved pain and craving control, reduced withdrawal symptoms, and greater psychotherapy engagement. Ketamine-assisted "bridge therapy" treatment may support opioid tapering in complex cases. This is a novel report to document a multifaceted improvement in this specific comorbidity cluster.

Comments

No comments yet.

Log in to comment